Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BLS PharmaceuticalsFRA:PR80 +6.68%38 Graham Number is €0.16 as of Dec. 2025, which is 100% below its 10-year median of 2.02. GuruFocus rates FRA:PR80 with a GF Score™ of 38/100 and a GF Value™ of €0.41 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 252 Biotechnology companies, BLS Pharmaceuticals ranks worse than 75% on this metric.
Graham Number is a figure that measures a stock's fundamental value by taking into account the company's earnings per share and book value per share. The Graham number is the upper bound of the price range that a defensive investor should pay for the stock. According to the theory, any stock price below the Graham number is considered undervalued, and thus worth investing in.
As of today (2026-07-14), the stock price of BLS Pharmaceuticals is €0.5781. BLS Pharmaceuticals's graham number for the quarter that ended in Dec. 2025 was €0.16. Therefore, BLS Pharmaceuticals's Price to Graham Number ratio for today is 3.72.
The historical rank and industry rank for BLS Pharmaceuticals's Graham Number or its related term are showing as below:
FRA:PR80'
s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.09 Med: 2.02 Max: 3.61
Current: 3.61
During the past 13 years, the highest Price to Graham Number ratio of BLS Pharmaceuticals was 3.61. The lowest was 1.09. And the median was 2.02.
FRA:PR80's Price-to-Graham-Number is ranked worse than 75% of 252
companies
in the Biotechnology industry
Industry Median: 1.845
vs FRA:PR80: 3.61
Graham Number is a combination of asset valuation and earnings power valuation. It is a very conservative way of valuing a stock.
BLS Pharmaceuticals (FRA:PR80) Graham Number Explanation
Ben Graham actually did not publish a formula like this. But he wrote in The Intelligent Investor (1948 version) regarding to the criteria for purchases:
Current price should not be more than 15 times average earnings of the past three years.
Current price should not be more than 1.5 times the book value last reported. However, a multiplier of earnings below 15 could justify a correspondingly higher multiplier of assets. As a rule of thumb we suggest that the product of the multiplier times the ratio of price to book value should not exceed 22.5. (This figure corresponds to 15 times earnings and 1.5 times book value. It would admit an issue selling at only 9 times earnings and 2.5 times asset value, etc.)
Unlike valuation methods such as DCF or Discounted Earnings, the Graham number does not take growth into the valuation. Unlike the valuation methods based on book value alone, it takes into account the earnings power. Therefore, the Graham Number is a combination of asset valuation and earnings power valuation.
In general, the Graham number is a very conservative way of valuing a stock. It cannot be applied to companies with negative book values.
BLS Pharmaceuticals's Price to Graham number Ratio for today is calculated as
Price to Graham number
=
Share Price (Today)
/
Graham number (Q: Dec. 2025 )
=
0.5781
/
0.16
=
3.72
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Please keep these in mind:
1. Graham Number does not take growth into account. Therefore it underestimates the values of the companies that have good earnings growth. We feel that if the earnings per share grows more than 10% a year, Graham Number underestimates the value.
2. Graham Number punishes the companies that have temporarily low earnings. Therefore, an average of earnings makes more sense in the calculation of Graham Number.
3. Graham Numbers underestimates companies that are light with book.
BLS Pharmaceuticals Graham Number Related Terms
BLS Pharmaceuticals Graham Number Historical Data
* Premium members only.
The historical data trend for BLS Pharmaceuticals's Graham Number can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, BLS Pharmaceuticals's Price-to-Graham-Number, along with its competitors' market caps and Price-to-Graham-Number data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BLS Pharmaceuticals Price-to-Graham-Number vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BLS Pharmaceuticals's Price-to-Graham-Number distribution charts can be found below:
* The bar in red indicates where BLS Pharmaceuticals's Price-to-Graham-Number falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BLS Pharmaceuticals (FRA:PR80) has a Graham Number of €0.16 as of Dec. 2025. The Graham Number values a company based on its per-share earnings and book value. View historical data on BLS Pharmaceuticals and its competitors. This is 92% below median its historical median of 2.02. Over the past decade, BLS Pharmaceuticals' Graham Number has ranged from 1.09 to 3.61. According to the industry distribution chart, BLS Pharmaceuticals ranks #189 out of 252 companies in the Biotechnology industry, placing it in the top 75%.
Is BLS Pharmaceuticals' Graham Number too high?
BLS Pharmaceuticals' current Graham Number of €0.16 is 92% below median its 10-year median of 2.02. Over the past 10 years, this metric has ranged from a low of 1.09 to a high of 3.61. Based on the distribution chart, BLS Pharmaceuticals ranks #189 out of 252 companies in the Biotechnology industry, which is below the industry midpoint. Overall, BLS Pharmaceuticals has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BLS Pharmaceuticals' Graham Number compare to ?
According to the Biotechnology industry distribution chart, BLS Pharmaceuticals ranks #189 out of 252 companies for Graham Number. This places BLS Pharmaceuticals in the lower half of its industry. The industry median Graham Number is 1.85. Historically, BLS Pharmaceuticals' own Graham Number has ranged from 1.09 to 3.61 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Graham Number for a Biotechnology company?
The median Graham Number among Biotechnology companies is 1.85, based on 252 companies in the industry. Companies in the top quartile (top 25%) have a Graham Number significantly above this median, while those in the bottom quartile fall well below. However, Graham Number should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Graham Number mean?
A high Graham Number can signal that a stock is expensive relative to its fundamentals. The Graham Number values a company based on its per-share earnings and book value. View historical data on BLS Pharmaceuticals and its competitors. For the Biotechnology industry, the median Graham Number is 1.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BLS Pharmaceuticals's current Graham Number is €0.16, which is 92% below median its own 10-year median of 2.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BLS Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, BLS Pharmaceuticals (FRA:PR80) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.41, compared to a current price of €0.58 — trading 41% above its estimated fair value. The current Graham Number is €0.16, which is 92% below median its 10-year median of 2.02. BLS Pharmaceuticals' overall GF Score™ is 38/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Graham Number calculated?
Graham Number is calculated from a company's financial statements. For BLS Pharmaceuticals (FRA:PR80), the current Graham Number is €0.16 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BLS Pharmaceuticals (FRA:PR80) Overvalued in 2026?
Based on GuruFocus' analysis, BLS Pharmaceuticals stock appears to be overvalued.
The current stock price of €0.58 is trading 41% above its estimated GF Value™ of €0.41.
GuruFocus considers BLS Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for FRA:PR80:
Graham Number: €0.16 (92% below median its 10-year median of 2.02)
GF Value™: €0.41 vs. price of €0.58 (41% above fair value)
No single metric tells the full story. See the FRA:PR80 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bioxyne Ltd is an Australian life science and health products company. The company is engaged in the development, manufacture, and distribution of consumer dietary supplements based on the proprietary probiotic strain of Lactobacillus fermentum PCC. Some of its products include Breathe Life Science, Dr Watson, BLS Clinics, Mirai Solution, CanXChange, and others. The company operates in segments, namely, Pharmaceutical manufacture and wholesale supply (business to business), Manufacture and distribution (wholesale, online, and retail), and Wholesale of patented Probiotics.
38GF Score
Get the complete analysis for FRA:PR80
Graham Number is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PR80 has been successfully added to your 
